国家创新药慧眼系统深圳建！“情报中枢”突破“卡脖子”瓶颈

Core Insights - The "Huiyan System" for innovative drugs was launched at the 17th China Bio-Industry Conference, aiming to address key pain points in the development of China's innovative drug industry [2][4] - Shenzhen is emerging as a hub for innovative drugs and high-end medical devices, with the pharmaceutical industry projected to reach a value of 54.783 billion yuan and the medical device industry approximately 103 billion yuan by 2024 [2][5] Group 1: Innovative Drug System - The "Huiyan System" is designed to meet the increasing domestic demand for high-quality, accessible, and affordable innovative drugs amid an aging population and rising health consumption [4] - The system addresses various pain points, including real-time updates on the innovative drug industry, insights into technological trends, and support for enterprises facing R&D bottlenecks and funding gaps [4] Group 2: Financial Empowerment - The Shenzhen local financial management bureau and the Shenzhen Securities Regulatory Bureau have issued a plan to cultivate patient capital, focusing on industries like artificial intelligence and biomedicine [5] - The plan aims to create a comprehensive financial support system covering R&D, pilot testing, mass production, and marketization, enhancing the efficiency of capital allocation in the pharmaceutical and medical device sectors [5]